Survival analysis of unexpected small cell lung cancer following surgery.
10.3760/cma.j.cn112152-20210209-00126
- VernacularTitle:术后意外的小细胞肺癌生存分析
- Author:
Jun Tang GUO
1
;
Lei Lei SHEN
2
;
Chao Yang LIANG
1
;
Xi LIU
1
;
Tao ZHANG
1
;
Yong Fu MA
1
;
Yang LIU
1
Author Information
1. Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Thoracic Surgery, Hainan Hospital, Chinese PLA General Hospital, Sanya 572000, China.
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Overall survival;
Small cell lung cancer;
Surgery
- MeSH:
Humans;
Lung Neoplasms/pathology*;
Lymph Node Excision;
Neoplasm Staging;
Prognosis;
Retrospective Studies;
Small Cell Lung Carcinoma/surgery*;
Survival Analysis
- From:
Chinese Journal of Oncology
2022;44(6):550-554
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the survival and influencing factors of unexpected small cell lung cancer following surgery. Methods: We respectively reviewed the clinical characters of 104 patients who underwent surgical treatment and be proved as small cell lung cancer by pathology between January 2000 to October 2020 in Chinese PLA General Hospital. Overall survival (OS) of patients was evaluated using Kaplan-Meier and Cox proportional hazards analysis. Results: Of 104 patients, 27 cases showed central lesions, and other 77 showed peripheral nodules. The margin of nodules was smooth in 42 cases on CT imaging. The median OS was 34.3 months and 5-year OS rate was 45.8%. Postoperative 5-year OS rates for patients were 52.1%, 45.4%, and 27.8% for clinical stages Ⅰ, Ⅱ, and Ⅲ, respectively. Univariate analyses identified the age, surgical access, surgical approach, N stage, TNM stage and vascular cancer emboli were associated with OS (P<0.05). The N stage was an independent factor for the OS of patients (P<0.05). Conclusions: Patients with unexpected SCLC, including Ⅰ, Ⅱ and part ⅢA stage have favorable outcome and can benefit from surgery and systemic postoperative treatment. Standard lobectomy plus systemic lymph node dissection is commended.
